2030 年までの北米感染症治療薬市場予測 - 地域別分析 - 薬剤クラス別 (抗ウイルス、抗菌、抗真菌、その他)、適応症別 (HIV、肝炎、結核、インフルエンザ、HPV、その他)、投与経路別 (経口、非経口、局所、その他)、流通チャネル別 (病院薬局、小売薬局、その他)
感染症の蔓延の増加が北米の感染症治療薬市場を活性化
感染症は、ウイルス、寄生虫、細菌、真菌、有毒物質、その他の感染性病原体によって引き起こされます。HIVは世界中で大きな公衆衛生問題となっています。国連エイズ合同計画（UNAIDS）によると、2020年に約3,770万人がHIVに感染していました。このうち、3,600万人が成人、170万人が0～14歳の子供でした。また、半数以上（53％）が少女と女性でした。さらに、2020年には世界中で150万人の新たなHIV感染者が報告されました。同様に、肝炎はウイルス感染によって引き起こされる肝臓の感染症です。肝炎ウイルスの主な種類は、A、B、C、D、Eです。世界保健機関（WHO）によると、世界中で約5,800万人が慢性C型肝炎ウイルス感染症に苦しんでおり、毎年約150万人の新規感染が発生しています。
WHOによると、結核（TB）は世界で13番目に多い死因であり、COVID-19に次ぐ2番目に多い感染症です。2020年には、150万人が結核で亡くなりました（HIVに感染した214,000人を含む）。さらに、2020年には世界中で1,000万人が結核に罹患し、そのうち110万人が子供、330万人が女性、560万人が男性でした。さらに、院内感染や医療関連感染（HAI）は罹患率と死亡率が高く、医療システムへの支出も毎年膨大です。米国疾病予防管理センター（CDC）は、アメリカの病院で毎年約170万件の感染症例と99,000人の死亡者がHAIによるものだと報告しています。したがって、世界中で感染症の蔓延が進んでいることが、感染症治療薬市場の成長を牽引しています。
北米の感染症治療薬市場の概要
北米の感染症治療薬市場は、米国、カナダ、メキシコに分かれています。北米は2022年に世界市場で最大のシェアを占めました。技術革新の採用の増加と研究開発活動の増加により、感染症治療薬市場の成長が加速すると予測されています。さらに、大規模なヘルスケアビジネスと、慢性疾患やウイルス性疾患を治療するための高度な治療ソリューションに対する需要の高まりが、この地域の市場拡大を推進しています。抗ウイルス療法の採用拡大による抗ウイルス剤の需要の急増が、米国の市場を牽引すると予想されています。大手医薬品・バイオ医薬品企業は、抗ウイルス剤の製造能力の拡大に注力しています。例えば、カリフォルニア州のギリアド・サイエンシズ社は、2020年5月にCOVID-19の治療薬として治験中の抗ウイルス剤レムデシビルのFDA承認を取得しました。さらに、2022年4月には、米国食品医薬品局（FDA）が、生後28日以上、体重3kg以上、COVID-19治療のために入院している、または軽度から中等度のCOVID-19感染症を患っている小児患者の治療薬として、ギリアド・サイエンシズによるベクルリー（レムデシビル）の追加新薬申請（sNDA）を承認しました。 2021年9月、バイデン・ハリス政権は、疾病対策センター（CDC）を通じて21億米ドルを投資し、国の公衆衛生および医療セクター全体の感染管理および予防活動を改善しました。これらの要因により、予測期間中に米国の感染症治療薬市場の成長が促進されると予想されます。
北米の感染症治療薬市場の収益と2030年までの予測（百万米ドル）
北米の感染症治療薬市場のセグメンテーション
北米の感染症治療薬市場は、薬物クラス、適応症、投与経路、流通チャネル、および国に分類されています。
薬物クラスに基づいて、北米の感染症治療薬市場は、抗ウイルス、抗菌、抗真菌、その他に分類されています。 2022年には抗ウイルスセグメントが最大の市場シェアを占めました。
適応症別に見ると、北米の感染症治療薬市場は、HIV、肝炎、結核、インフルエンザ、HPVなどに分類されています。2022年にはHIVが最大の市場シェアを占めました。
投与経路別に見ると、北米の感染症治療薬市場は、経口、非経口、局所などに分類されています。2022年には経口セグメントが最大の市場シェアを占めました。
流通チャネル別に見ると、北米の感染症治療薬市場は、病院薬局、小売薬局などに分類されています。2022年には病院薬局が最大の市場シェアを占めました。
国別に見ると、北米の感染症治療薬市場は、米国、カナダ、メキシコに分類されています。 2022年、北米の感染症治療薬市場シェアは米国が独占しました。
北米の感染症治療薬市場で事業を展開している大手企業には、AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc、Shionogi & Co Ltdなどがあります。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.4.2 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - North America Market Analysis
5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Infectious Disease Therapeutics Market - Country Analysis
10.1 North America Infectious Disease Therapeutics Market Overview
10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. North America Infectious Disease Therapeutics Market Segmentation
Table 2. Diseases and Funding
Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.